Arjuna Capital Sells 6,116 Shares of Novo Nordisk A/S (NYSE:NVO)

Arjuna Capital decreased its position in Novo Nordisk A/S (NYSE:NVO) by 11.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 47,267 shares of the company’s stock after selling 6,116 shares during the quarter. Novo Nordisk A/S accounts for 1.5% of Arjuna Capital’s portfolio, making the stock its 17th biggest holding. Arjuna Capital’s holdings in Novo Nordisk A/S were worth $5,628,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in NVO. William Blair Investment Management LLC increased its stake in Novo Nordisk A/S by 2.3% in the 1st quarter. William Blair Investment Management LLC now owns 53,423 shares of the company’s stock worth $6,860,000 after acquiring an additional 1,185 shares during the last quarter. Edmond DE Rothschild Holding S.A. bought a new position in shares of Novo Nordisk A/S during the 1st quarter valued at approximately $80,000. TD Asset Management Inc increased its position in shares of Novo Nordisk A/S by 10.9% during the 1st quarter. TD Asset Management Inc now owns 1,074,022 shares of the company’s stock valued at $137,904,000 after purchasing an additional 105,523 shares during the last quarter. D Orazio & Associates Inc. increased its position in shares of Novo Nordisk A/S by 4.4% during the 1st quarter. D Orazio & Associates Inc. now owns 8,655 shares of the company’s stock valued at $1,111,000 after purchasing an additional 362 shares during the last quarter. Finally, Planning Directions Inc. increased its position in shares of Novo Nordisk A/S by 4.0% during the 1st quarter. Planning Directions Inc. now owns 2,916 shares of the company’s stock valued at $374,000 after purchasing an additional 112 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on NVO shares. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. BMO Capital Markets cut their target price on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Stock Up 0.1 %

Shares of NVO stock traded up $0.13 during mid-day trading on Wednesday, hitting $107.19. The stock had a trading volume of 441,864 shares, compared to its average volume of 4,428,569. Novo Nordisk A/S has a 12-month low of $94.73 and a 12-month high of $148.15. The firm has a market capitalization of $481.02 billion, a P/E ratio of 34.64, a price-to-earnings-growth ratio of 1.32 and a beta of 0.42. The firm’s 50-day moving average is $120.23 and its two-hundred day moving average is $130.08. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.